Tissue | Expression Dynamics | Abbreviation |
Colorectum (GSE201348) | | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Esophagus | | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Oral Cavity | | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | | BPH: Benign Prostatic Hyperplasia |
Thyroid | | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:001907920 | Oral cavity | OSCC | viral genome replication | 95/7305 | 131/18723 | 6.35e-15 | 4.02e-13 | 95 |
GO:000961515 | Oral cavity | OSCC | response to virus | 215/7305 | 367/18723 | 1.63e-14 | 9.41e-13 | 215 |
GO:009031610 | Oral cavity | OSCC | positive regulation of intracellular protein transport | 110/7305 | 160/18723 | 2.10e-14 | 1.19e-12 | 110 |
GO:004312218 | Oral cavity | OSCC | regulation of I-kappaB kinase/NF-kappaB signaling | 155/7305 | 249/18723 | 7.79e-14 | 4.14e-12 | 155 |
GO:004682217 | Oral cavity | OSCC | regulation of nucleocytoplasmic transport | 79/7305 | 106/18723 | 1.04e-13 | 5.37e-12 | 79 |
GO:004312310 | Oral cavity | OSCC | positive regulation of I-kappaB kinase/NF-kappaB signaling | 122/7305 | 186/18723 | 1.68e-13 | 8.52e-12 | 122 |
GO:000724910 | Oral cavity | OSCC | I-kappaB kinase/NF-kappaB signaling | 169/7305 | 281/18723 | 4.69e-13 | 2.25e-11 | 169 |
GO:005079220 | Oral cavity | OSCC | regulation of viral process | 109/7305 | 164/18723 | 8.95e-13 | 4.10e-11 | 109 |
GO:190018210 | Oral cavity | OSCC | positive regulation of protein localization to nucleus | 66/7305 | 87/18723 | 2.74e-12 | 1.10e-10 | 66 |
GO:190018015 | Oral cavity | OSCC | regulation of protein localization to nucleus | 93/7305 | 136/18723 | 3.46e-12 | 1.35e-10 | 93 |
GO:190390020 | Oral cavity | OSCC | regulation of viral life cycle | 97/7305 | 148/18723 | 5.34e-11 | 1.67e-09 | 97 |
GO:00516074 | Oral cavity | OSCC | defense response to virus | 154/7305 | 265/18723 | 1.96e-10 | 5.63e-09 | 154 |
GO:01405464 | Oral cavity | OSCC | defense response to symbiont | 154/7305 | 265/18723 | 1.96e-10 | 5.63e-09 | 154 |
GO:004506917 | Oral cavity | OSCC | regulation of viral genome replication | 62/7305 | 85/18723 | 2.14e-10 | 6.04e-09 | 62 |
GO:00343405 | Oral cavity | OSCC | response to type I interferon | 46/7305 | 58/18723 | 4.17e-10 | 1.11e-08 | 46 |
GO:00603374 | Oral cavity | OSCC | type I interferon signaling pathway | 41/7305 | 50/18723 | 5.59e-10 | 1.46e-08 | 41 |
GO:00713574 | Oral cavity | OSCC | cellular response to type I interferon | 42/7305 | 52/18723 | 8.50e-10 | 2.13e-08 | 42 |
GO:00511709 | Oral cavity | OSCC | import into nucleus | 100/7305 | 159/18723 | 8.67e-10 | 2.15e-08 | 100 |
GO:00066069 | Oral cavity | OSCC | protein import into nucleus | 97/7305 | 155/18723 | 2.27e-09 | 5.30e-08 | 97 |
GO:00028317 | Oral cavity | OSCC | regulation of response to biotic stimulus | 177/7305 | 327/18723 | 1.73e-08 | 3.43e-07 | 177 |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa05171 | Colorectum | AD | Coronavirus disease - COVID-19 | 113/2092 | 232/8465 | 9.90e-16 | 2.55e-14 | 1.63e-14 | 113 |
hsa05160 | Colorectum | AD | Hepatitis C | 54/2092 | 157/8465 | 3.87e-03 | 1.96e-02 | 1.25e-02 | 54 |
hsa051711 | Colorectum | AD | Coronavirus disease - COVID-19 | 113/2092 | 232/8465 | 9.90e-16 | 2.55e-14 | 1.63e-14 | 113 |
hsa051601 | Colorectum | AD | Hepatitis C | 54/2092 | 157/8465 | 3.87e-03 | 1.96e-02 | 1.25e-02 | 54 |
hsa051712 | Colorectum | SER | Coronavirus disease - COVID-19 | 98/1580 | 232/8465 | 3.33e-17 | 8.50e-16 | 6.17e-16 | 98 |
hsa051713 | Colorectum | SER | Coronavirus disease - COVID-19 | 98/1580 | 232/8465 | 3.33e-17 | 8.50e-16 | 6.17e-16 | 98 |
hsa051714 | Colorectum | MSS | Coronavirus disease - COVID-19 | 108/1875 | 232/8465 | 6.50e-17 | 1.67e-15 | 1.03e-15 | 108 |
hsa051602 | Colorectum | MSS | Hepatitis C | 52/1875 | 157/8465 | 9.29e-04 | 5.58e-03 | 3.42e-03 | 52 |
hsa05169 | Colorectum | MSS | Epstein-Barr virus infection | 63/1875 | 202/8465 | 1.63e-03 | 8.98e-03 | 5.50e-03 | 63 |
hsa05161 | Colorectum | MSS | Hepatitis B | 48/1875 | 162/8465 | 1.53e-02 | 4.93e-02 | 3.02e-02 | 48 |
hsa051715 | Colorectum | MSS | Coronavirus disease - COVID-19 | 108/1875 | 232/8465 | 6.50e-17 | 1.67e-15 | 1.03e-15 | 108 |
hsa051603 | Colorectum | MSS | Hepatitis C | 52/1875 | 157/8465 | 9.29e-04 | 5.58e-03 | 3.42e-03 | 52 |
hsa051691 | Colorectum | MSS | Epstein-Barr virus infection | 63/1875 | 202/8465 | 1.63e-03 | 8.98e-03 | 5.50e-03 | 63 |
hsa051611 | Colorectum | MSS | Hepatitis B | 48/1875 | 162/8465 | 1.53e-02 | 4.93e-02 | 3.02e-02 | 48 |
hsa051718 | Colorectum | FAP | Coronavirus disease - COVID-19 | 78/1404 | 232/8465 | 9.94e-11 | 1.11e-08 | 6.73e-09 | 78 |
hsa051719 | Colorectum | FAP | Coronavirus disease - COVID-19 | 78/1404 | 232/8465 | 9.94e-11 | 1.11e-08 | 6.73e-09 | 78 |
hsa0517110 | Colorectum | CRC | Coronavirus disease - COVID-19 | 74/1091 | 232/8465 | 1.66e-14 | 2.78e-12 | 1.88e-12 | 74 |
hsa0517111 | Colorectum | CRC | Coronavirus disease - COVID-19 | 74/1091 | 232/8465 | 1.66e-14 | 2.78e-12 | 1.88e-12 | 74 |
hsa05169210 | Esophagus | ESCC | Epstein-Barr virus infection | 151/4205 | 202/8465 | 1.55e-13 | 3.45e-12 | 1.77e-12 | 151 |
hsa0516425 | Esophagus | ESCC | Influenza A | 122/4205 | 171/8465 | 5.01e-09 | 4.79e-08 | 2.45e-08 | 122 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
MAVS | SNV | Missense_Mutation | novel | c.967C>A | p.Pro323Thr | p.P323T | Q7Z434 | protein_coding | deleterious(0.02) | benign(0.047) | TCGA-A2-A0CP-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | SD |
MAVS | SNV | Missense_Mutation | novel | c.841N>G | p.Ile281Val | p.I281V | Q7Z434 | protein_coding | tolerated(0.1) | benign(0) | TCGA-A2-A0YM-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
MAVS | SNV | Missense_Mutation | rs762014329 | c.1460N>T | p.Ala487Val | p.A487V | Q7Z434 | protein_coding | tolerated(0.18) | benign(0.087) | TCGA-AC-A62X-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
MAVS | SNV | Missense_Mutation | novel | c.1249G>C | p.Glu417Gln | p.E417Q | Q7Z434 | protein_coding | deleterious(0.02) | possibly_damaging(0.728) | TCGA-E9-A3QA-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
MAVS | SNV | Missense_Mutation | novel | c.1216N>C | p.Asp406His | p.D406H | Q7Z434 | protein_coding | deleterious(0) | probably_damaging(0.958) | TCGA-LL-A5YO-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | taxotere | CR |
MAVS | insertion | Frame_Shift_Ins | novel | c.965_966insCCCTCAGAAATATATAGTTGTCCATCTG | p.Ser324GlnfsTer15 | p.S324Qfs*15 | Q7Z434 | protein_coding | | | TCGA-A2-A0CP-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | SD |
MAVS | SNV | Missense_Mutation | | c.545N>G | p.Ser182Cys | p.S182C | Q7Z434 | protein_coding | deleterious(0.04) | possibly_damaging(0.826) | TCGA-Q1-A73O-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
MAVS | SNV | Missense_Mutation | | c.1438N>C | p.Glu480Gln | p.E480Q | Q7Z434 | protein_coding | tolerated(0.22) | possibly_damaging(0.605) | TCGA-Q1-A73O-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
MAVS | SNV | Missense_Mutation | novel | c.835N>A | p.Glu279Lys | p.E279K | Q7Z434 | protein_coding | tolerated(0.33) | benign(0.02) | TCGA-AA-3994-01 | Colorectum | colon adenocarcinoma | Male | >=65 | III/IV | Chemotherapy | capecitabine | CR |
MAVS | SNV | Missense_Mutation | | c.1459N>A | p.Ala487Thr | p.A487T | Q7Z434 | protein_coding | tolerated(0.27) | benign(0.034) | TCGA-AZ-4615-01 | Colorectum | colon adenocarcinoma | Male | >=65 | III/IV | Chemotherapy | xeloda | PD |